Artizan Biosciences Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
19
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$482K
- Investors
-
9
Artizan Biosciences General Information
Description
Developer of precision therapeutics designed to target and block the root causes of diverse, serious diseases triggered by intestinal inflammation. The company's therapeutics identify and characterize disease-driving bacteria from the intestinal microbiota with the goal of developing new and potentially curative treatments for unmet medical needs, enabling patients to have treatment options for a number of digestive disorders as well as other diseases including obesity, autoimmune disease, and a wide variety of skin, lung and central nervous system diseases.
Contact Information
Website
www.artizanbiosciences.comCorporate Office
- 25 Science Park at Yale
- 150 Munson Street, Suite 210
- New Haven, CT 06511
- United States
Corporate Office
- 25 Science Park at Yale
- 150 Munson Street, Suite 210
- New Haven, CT 06511
- United States
Artizan Biosciences Timeline
Artizan Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 10-Mar-2023 | $482K | Completed | Pre-Clinical Trials | ||
| 4. Later Stage VC (Series A2) | 15-Jun-2022 | Completed | Pre-Clinical Trials | |||
| 3. Debt - PPP | 11-Apr-2020 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 10-Jun-2019 | $12M | $15M | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC (Series A) | 06-Feb-2017 | $3M | $3M | Completed | Startup |
Artizan Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A2 | ||||||||
| Series A1 | ||||||||
| Series A | 6,735,325 | $0.001000 | 8% | $0.49 | $0.49 | 1x | $0.23 | 9.14% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Artizan Biosciences Comparisons
Industry
Financing
Details
Artizan Biosciences Competitors (13)
One of Artizan Biosciences’s 13 competitors is AnTolRx, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AnTolRx | Venture Capital-Backed | Cambridge, MA | ||||
| Codiak BioSciences | Formerly VC-backed | Cambridge, MA | ||||
| Evox Therapeutics | Venture Capital-Backed | Oxford, United Kingdom | ||||
| Caris Life Sciences | Private Equity-Backed | Irving, TX | ||||
| Oncorus | Formerly VC-backed | Andover, MA |
Artizan Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Artizan Biosciences Patents
Artizan Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3232883-A1 | Small molecule inhibitors of bacterial toxins | Pending | 24-Sep-2021 | ||
| EP-4405330-A1 | Small molecule inhibitors of bacterial toxins | Pending | 24-Sep-2021 | ||
| AU-2021339828-A1 | Small molecule inhibitors of bacterial toxins | Pending | 11-Sep-2020 | ||
| CA-3192162-A1 | Small molecule inhibitors of bacterial toxins | Pending | 11-Sep-2020 | ||
| EP-4210738-A2 | Small molecule inhibitors of bacterial toxins | Pending | 11-Sep-2020 | C07C311/29 |
Artizan Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Artizan Biosciences Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AlleyCorp | Venture Capital | Minority | ||
| Biohaven | Corporation | Minority | ||
| Brii Biosciences | Corporation | Minority | ||
| Connecticut Innovations | Venture Capital | Minority | ||
| Johnson & Johnson Innovation - JJDC | Corporate Venture Capital | Minority |
Artizan Biosciences FAQs
-
When was Artizan Biosciences founded?
Artizan Biosciences was founded in 2016.
-
Where is Artizan Biosciences headquartered?
Artizan Biosciences is headquartered in New Haven, CT.
-
What is the size of Artizan Biosciences?
Artizan Biosciences has 19 total employees.
-
What industry is Artizan Biosciences in?
Artizan Biosciences’s primary industry is Drug Discovery.
-
Is Artizan Biosciences a private or public company?
Artizan Biosciences is a Private company.
-
What is Artizan Biosciences’s current revenue?
The current revenue for Artizan Biosciences is .
-
How much funding has Artizan Biosciences raised over time?
Artizan Biosciences has raised $34.4M.
-
Who are Artizan Biosciences’s investors?
AlleyCorp, Biohaven, Brii Biosciences, Connecticut Innovations, and Johnson & Johnson Innovation - JJDC are 5 of 9 investors who have invested in Artizan Biosciences.
-
Who are Artizan Biosciences’s competitors?
AnTolRx, Codiak BioSciences, Evox Therapeutics, Caris Life Sciences, and Oncorus are some of the 13 competitors of Artizan Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
